BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34101869)

  • 41. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.
    Han SX; Bai E; Jin GH; He CC; Guo XJ; Wang LJ; Li M; Ying X; Zhu Q
    J Immunol Res; 2014; 2014():261365. PubMed ID: 24860833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells.
    Zhang H; Yu QL; Meng L; Huang H; Liu H; Zhang N; Liu N; Yang J; Zhang YZ; Huang Q
    Arch Biochem Biophys; 2020 Oct; 693():108571. PubMed ID: 32898567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells.
    Lei L; Wu J; Gu D; Liu H; Wang S
    Tumour Biol; 2016 Aug; 37(8):11073-9. PubMed ID: 26906552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation.
    Feng L; Chen Y; Li N; Yang X; Zhou L; Li H; Wang T; Xie M; Liu H
    Life Sci; 2023 Jun; 322():121671. PubMed ID: 37023953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
    Chen R; Zhu S; Fan XG; Wang H; Lotze MT; Zeh HJ; Billiar TR; Kang R; Tang D
    Hepatology; 2018 May; 67(5):1823-1841. PubMed ID: 29149457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma.
    Higashi T; Hayashi H; Kitano Y; Yamamura K; Kaida T; Arima K; Taki K; Nakagawa S; Okabe H; Nitta H; Imai K; Hashimoto D; Chikamoto A; Beppu T; Baba H
    Med Oncol; 2016 Nov; 33(11):123. PubMed ID: 27734263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. YAP/TAZ Mediate TGFβ2-Induced Schlemm's Canal Cell Dysfunction.
    Li H; Singh A; Perkumas KM; Stamer WD; Ganapathy PS; Herberg S
    Invest Ophthalmol Vis Sci; 2022 Nov; 63(12):15. PubMed ID: 36350617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
    Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
    Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients.
    Sweed D; Abd-Elbary A; Sweed E; Mosbeh A; Moaz I; Yassein T; Elmashad S
    Pol J Pathol; 2022; 73(2):88-98. PubMed ID: 35979755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling.
    Xu Q; Zhuo K; Zhang X; Zhen Y; Liu L; Zhang L; Gu Y; Jia H; Chen Q; Liu M; Dong J; Zhou MS
    Eur J Pharmacol; 2024 Jan; 962():176252. PubMed ID: 38061470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
    Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
    Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
    Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
    Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [YAP induces chromosomal instability in liver cancer patients].
    Weiler S
    Pathologe; 2018 Dec; 39(Suppl 2):185-188. PubMed ID: 30206654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
    Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
    Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation.
    Garoffolo G; Casaburo M; Amadeo F; Salvi M; Bernava G; Piacentini L; Chimenti I; Zaccagnini G; Milcovich G; Zuccolo E; Agrifoglio M; Ragazzini S; Baasansuren O; Cozzolino C; Chiesa M; Ferrari S; Carbonaro D; Santoro R; Manzoni M; Casalis L; Raucci A; Molinari F; Menicanti L; Pagano F; Ohashi T; Martelli F; Massai D; Colombo GI; Messina E; Morbiducci U; Pesce M
    Circ Res; 2022 Jul; 131(3):239-257. PubMed ID: 35770662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
    Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
    Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
    EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.